Factory Direct XCE Tirzepatide - Dual Action Weight Management Compound

XCE tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for research purposes. This 39-amino acid peptide features two non-natural residues (Aib at positions 2 and 13) and a C20 fatty diacid side chain at Lys20, contributing to its extended research potential.

The compound demonstrates significant research potential in weight management studies, with clinical trials showing promising results. Its dual-action mechanism (GLP-1/GIP receptor agonist) makes it particularly interesting for metabolic research applications.

Our XCE tirzepatide is produced under strict quality control measures, ensuring high purity and consistency for research applications. The product is available in various concentrations to meet different research requirements.

For research purposes, typical study protocols begin with lower concentrations (2.5mg) with potential escalation based on experimental design. The extended half-life (~117 hours) allows for flexible research scheduling.

This product is intended for laboratory research use only. All handling should be performed by qualified researchers following appropriate safety protocols. The material should be stored properly to maintain stability.